Figure 5.

Concomitant inhibition of AR and EZH2 enhances cytotoxic activity and cytokine production of tumor-specific CD8⁺ T cells.

(A) Scheme of the in vivo cytotoxicity assay in TRAMP mice. 15-week-old TRAMP mice were treated with enzalutamide, GSK-126, or their combination (Combo). 2 weeks later treated TRAMP and control non-tumor-bearing naive C57BL/6 (B6) mice were immunized with DCs pulsed with Tag_IV peptide. 1 week later, in vivo cytotoxicity was tested as described in methods (B). From these mice we also evaluated frequency (C) and cytokine production (D) of prostate-infiltrating immune cells, after 4 h stimulation with PMA-ionomycin and brefeldin A. Histograms report mean ± SD, each dot is a mouse. One-way ANOVA followed by Tukey's multiple comparison test: *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. Where p-value is not indicated, the comparison between groups is not statistically significant.